Table 1 |
|||||
|
Baseline characteristics for training and test datasets |
|||||
|
Placebo + MTX |
Golimumab 100 mg + placebo |
Golimumab 50 mg + MTX |
Golimumab 100 mg + MTX |
Total |
|
|
|
|||||
|
Training dataset |
|||||
|
Number |
21 |
30 |
21 |
28 |
100 |
|
Age (years) |
50 ± 12 (24-76) |
50 ± 12 (22-71) |
53 ± 11 (25-68) |
52 ± 9 (38-76) |
51 ± 11 (22-76) |
|
Weight (kg) |
70 ± 13 (47-97) |
72 ± 15 (47-104) |
69 ± 18 (43-108) |
75 ± 22 (47-120) |
72 ± 17 (43-120) |
|
Sex (% men) |
10% |
20% |
10% |
21% |
16% |
|
Race (% Caucasian) |
76% |
67% |
67% |
75% |
71% |
|
CRP (μg/ml) |
1.97 ± 2.54 (0.3-10.8) |
2.16 ± 2.77 (0.3-11.7) |
1.20 ± 1.53 (0.3-7.0) |
1.38 ± 1.44 (0.3-6.2) |
1.70 ± 2.18 (0.30-11.7) |
|
Swollen joint count |
13.0 ± 5.7 (5-26) |
13.9 ± 10.4 (5-51) |
12.5 ± 9.2 (4-48) |
14.2 ± 9.6 (5-43) |
13.5 ± 9.0 (4-51) |
|
Tender joint count |
21.3 ± 12.3 (6-62) |
21.4 ± 13.1 (5-58) |
23.2 ± 16.8 (4-63) |
24.1 ± 13.4 (6-53) |
22.5 ± 13.7 (4-63) |
|
FACIT-F (0-52) |
26 ± 11 (4-50) |
26 ± 10 (4-50) |
27 ± 12 (12-50) |
26 ± 11 (4-50) |
|
|
SF-36 mental component summary score (0-100) |
44 ± 9 (20-61) |
45 ± 11 (26-61) |
44 ± 11 (24-62) |
44 ± 10 (20-62) |
|
|
SF-36 physical component summary score (0-100) |
30 ± 8 (17-54) |
32 ± 9 (18-51) |
33 ± 8 (19-52) |
31 ± 8 (17-54) |
|
|
Test dataset |
|||||
|
Number |
N/A |
102 |
68 |
66 |
236 |
|
Age (years) |
50 ± 11 (21-74) |
50 ± 11 (18-79) |
50 ± 10 (23-72) |
50 ± 11 (18-79) |
|
|
Weight (kg) |
74 ± 17 (42-135) |
74 ± 18 (39-146) |
71 ± 17 (40-136) |
73 ± 17 (39-146) |
|
|
Sex (% men) |
22% |
22% |
21% |
22% |
|
|
Race (% Caucasian) |
82% |
76% |
82% |
81% |
|
|
CRP (μg/ml) |
1.84 ± 2.27 (0.3-15.1) |
2.23 ± 2.54 (0.3-11.5) |
1.98 ± 2.68 (0.3-16.8) |
1.99 ± 2.47 (0.3-16.8) |
|
|
Swollen/tender joint count |
41.0 ± 21.6 (10-88) |
47.4 ± 23.0 (10-105) |
41.7 ± 21.0 (9-100) |
43.0 ± 21.9 (9-105) |
|
|
Swollen joint count |
15.0 ± 10.6 (4-59) |
18.0 ± 12.3 (4-53) |
14.8 ± 9.7 (4-45) |
15.8 ± 10.9 (4-59) |
|
|
Tender joint count |
26.0 ± 15.9 (5-68) |
29.3 ± 15.3 (5-68) |
27.0 ± 15.0 (4-62) |
27.2 ± 15.5 (4-68) |
|
|
FACIT-F (0-52) |
29 ± 11 (5-50) |
27 ± 11 (6-50) |
26 ± 10 (6-47) |
27 ± 11 (5-50) |
|
|
SF-36 mental component summary score (0-100) |
44 ± 12 (19-73) |
44 ± 11 (19-73) |
43 ± 12 (17-68) |
43 ± 11 (17-73) |
|
|
SF-36 physical component summary score (0-100) |
31 ± 9 (15-54) |
30 ± 8 (16-49) |
29 ± 8 (12-46) |
30 ± 8 (12-54) |
|
|
|
|||||
|
Values are expressed as mean ± standard deviation (range), unless otherwise indicated. CRP, C-reactive protein; FACIT-F, Functional Assessment of Chronic Illness Therapy-Fatigue; MTX, methotrexate; SF-36, 36-question Short Form Survey. |
|||||
|
Visvanathan et al. Arthritis Research & Therapy 2010 12:R211 doi:10.1186/ar3188 |
|||||
